The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

Completed

Conditions studied: Diabetes, HIV Infections, Insulin Resistance

In brief

The purpose of this study is to determine the mechanisms by which HIV protease inhibitors contribute to the development of diabetes in HIV-infected patients. The investigators propose that some HIV protease inhibitors impair insulin secretion and increase the production of glucose by the liver.

Key facts

Study ID

NCT00259727

Run by

US Department of Veterans Affairs

People needed

80

Starts

2006-01-01

Expected to finish

2008-09-01

Last updated by the study team

2009-09-30

Who can join

Age: 18 and older, up to 72. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy, HIV-negative volunteers between the ages of 18-72 years

You may not qualify if…

• Any subject with states known to be associated with insulin resistance, such as impaired fasting glucose (glucose > 110 mg/dl), overweight (body mass index [BMI] > 27), dyslipidemia (triglycerides > 150 mg/dl), hypertension (blood pressure [BP] > 130/85 mmHg or on medication), renal disease, systemic use of glucocorticoids, growth hormone, niacin, or antipsychotics.
• Women will be tested for pregnancy immediately prior to study and excluded if pregnant.

Where it is running

• VA Medical Center, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.